Heska Corp (HSKA) to Post FY2018 Earnings of $1.71 Per Share, B. Riley Forecasts

Heska Corp (NASDAQ:HSKA) – Equities researchers at B. Riley raised their FY2018 EPS estimates for shares of Heska in a research report issued to clients and investors on Wednesday, November 7th. B. Riley analyst K. Anderson now anticipates that the medical research company will post earnings of $1.71 per share for the year, up from their previous estimate of $1.62. B. Riley also issued estimates for Heska’s Q1 2019 earnings at $0.50 EPS.

Several other brokerages have also commented on HSKA. Benchmark began coverage on shares of Heska in a research report on Thursday, July 19th. They set a “buy” rating and a $120.00 target price on the stock. Zacks Investment Research upgraded shares of Heska from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 18th. BidaskClub lowered shares of Heska from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 27th. TheStreet lowered shares of Heska from a “b” rating to a “c+” rating in a research report on Monday, August 20th. Finally, ValuEngine lowered shares of Heska from a “buy” rating to a “hold” rating in a research report on Monday, July 30th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $107.50.

Shares of NASDAQ HSKA opened at $102.99 on Friday. The firm has a market cap of $756.30 million, a price-to-earnings ratio of 49.75 and a beta of 0.73. Heska has a one year low of $56.59 and a one year high of $114.50.

Heska (NASDAQ:HSKA) last issued its earnings results on Tuesday, November 6th. The medical research company reported $0.46 EPS for the quarter, topping the consensus estimate of $0.35 by $0.11. The company had revenue of $30.96 million for the quarter, compared to analyst estimates of $31.14 million. Heska had a net margin of 1.01% and a return on equity of 11.48%.

Several institutional investors have recently added to or reduced their stakes in HSKA. State Board of Administration of Florida Retirement System raised its stake in Heska by 23.0% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 3,581 shares of the medical research company’s stock valued at $372,000 after purchasing an additional 670 shares during the last quarter. Globeflex Capital L P raised its stake in Heska by 18.2% in the 2nd quarter. Globeflex Capital L P now owns 5,700 shares of the medical research company’s stock valued at $592,000 after purchasing an additional 877 shares during the last quarter. Legal & General Group Plc raised its stake in Heska by 7.9% in the 2nd quarter. Legal & General Group Plc now owns 13,305 shares of the medical research company’s stock valued at $1,375,000 after purchasing an additional 969 shares during the last quarter. Rhumbline Advisers raised its stake in Heska by 6.3% in the 2nd quarter. Rhumbline Advisers now owns 16,376 shares of the medical research company’s stock valued at $1,700,000 after purchasing an additional 977 shares during the last quarter. Finally, Principal Financial Group Inc. raised its stake in Heska by 2.4% in the 1st quarter. Principal Financial Group Inc. now owns 49,975 shares of the medical research company’s stock valued at $3,952,000 after purchasing an additional 1,162 shares during the last quarter. Institutional investors and hedge funds own 88.63% of the company’s stock.

In related news, EVP Steven M. Eyl sold 33,351 shares of the business’s stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $98.49, for a total value of $3,284,739.99. Following the sale, the executive vice president now directly owns 15,401 shares in the company, valued at approximately $1,516,844.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Rod Lippincott sold 2,805 shares of the business’s stock in a transaction dated Friday, August 24th. The stock was sold at an average price of $104.01, for a total transaction of $291,748.05. Following the completion of the sale, the executive vice president now owns 11,078 shares in the company, valued at $1,152,222.78. The disclosure for this sale can be found here. Insiders sold a total of 56,777 shares of company stock worth $5,751,062 over the last quarter. Insiders own 14.70% of the company’s stock.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.

Recommended Story: What is a Reverse Stock Split?

Earnings History and Estimates for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply